Mass study into effect of anti-malaria drug on Covid-19 given go-ahead

Researchers will continue with efforts to recruit 40,000 health workers for a global study into the effects of an anti-malaria drug on Covid-19.

The effectiveness of hydroxychloroquine in the fight against coronavirus has been widely analysed, but studies were halted earlier this month.

The Medicines and Healthcare products Regulatory Agency (MHRA) decided to temporarily halt recruitment of volunteers for trials involving hydroxychloroquine until continuation of the tests could be justified.

MHRA said consent for the global study – called Copcov – has been granted earlier this week.



The trial, led by the University of Oxford’s Mahidol Oxford Tropical Research Unit in Bangkok, Thailand, had started enlisting volunteers in Brighton and Oxford to see whether the drug could prevent Covid-19.

Many recent studies had focused on seeing whether the drug can be used to treat, rather than prevent, coronavirus.

More than 40,000 healthcare workers from Europe, Africa, Asia and South America will be given chloroquine, hydroxychloroquine or a placebo.

The study’s UK lead investigator Professor Martin Llewelyn said: “Although rates of Covid are low just now in the UK, healthcare workers are still being affected across the NHS and a second wave of infection this winter is widely expected.

“In terms of finding an intervention that could protect key workers by this winter, hydroxychloroquine is by far the most realistic prospect.

“The recent post-exposure prophylaxis study confirmed its safety and indicated that it could be protective if given as pre-exposure prophylaxis. This is what Copcov will find out.”

The trial resumes after a now-retracted study claimed the drug was linked to an increased risk of death and heart arrhythmias among people severely ill in hospital with coronavirus.

The study, published in the Lancet medical journal, forced the World Health Organisation to temporarily pause the hydroxychloroquine arm of its Solidarity drug trials as a precaution to allow safety data to be reviewed.

However, its authors later retracted the study after concerns were raised about the veracity of data and analyses used, leading them to seek an independent audit.

.

About the Author: TEAM BEPINKU.COM

We share trending news and latest information on Business, Technology, Entertainment, Politics, Sports, Automobiles, Education, Jobs, Health, Lifestyle, Travel and more. That's our work. We are a team led by Mahammad Sakil Ansari.
Menu